BTK and B-cell chronic lymphocytic leukemia: Daratummab has a good therapeutic effect on CLL through ADCC, CDC, and ADCP, and apoptosis mechanisms CD38 reduced the enhancement effect of ibrutinib on Syk, BTK, PLCγ2, ERK1/2, and AKT.